Loading stock data...

Lyka Labs Limited

NSE: LYKALABS BSE: LYKALABS

NSE
61.82 0.46 (0.75%)

Prev Close

61.36

Open Price

60.2

Volume

41,521

Today Low / High

60.2 / 62.99

52 WK Low / High

60.2 / 128.78

Range

59 - 65

BSE
61.30 0.17 (0.28%)

Prev Close

61.13

Open Price

60

Volume

715

Today Low / High

60 / 61.9

52 WK Low / High

60 / 143.8

Range

58 - 64

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 61.82 (target range: 59 - 65), reflecting a change of 0.46 (0.74967%). On the BSE, it is listed at 61.3 (target range: 58 - 64), showing a change of 0.17 (0.2781%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.

25 Feb 60.20 2.69%
24 Feb 62.23 -1.40%
23 Feb 63.40 -1.85%
20 Feb 65.79 -4.39%
19 Feb 68.98 -4.38%
18 Feb 67.98 -1.07%
17 Feb 67.23 1.12%
16 Feb 68.30 -0.41%
13 Feb 70.00 -1.34%
12 Feb 72.00 -2.49%
11 Feb 72.88 -1.34%
10 Feb 71.59 1.80%
09 Feb 73.00 -3.99%
06 Feb 71.15 -0.72%
05 Feb 72.95 -2.03%
04 Feb 72.70 -0.77%
03 Feb 72.00 -2.01%
02 Feb 72.30 -2.05%
01 Feb 71.05 1.27%
30 Jan 73.75 -2.73%
29 Jan 75.03 -2.23%
28 Jan 72.25 3.85%

Lyka Labs Limited Graph

Lyka Labs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Lyka Labs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 61.82, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 61.30 61.91 55.72 - 68.10
62.53 50.02 - 75.03
63.14 44.20 - 82.08
Bearish Scenario 61.30 60.69 54.62 - 66.76
60.07 48.06 - 72.09
59.46 41.62 - 77.30

Overview of Lyka Labs Limited

ISIN

INE933A01014

Industry

Biotechnology

Vol.Avg

27,212

Market Cap

2,206,355,800

Last Dividend

0

Official Website

Visit Website

IPO Date

1996-01-01

DCF Diff

-89.89

DCF

170

Financial Ratios Every Investor Needs

Stock Dividend of LYKALABS

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
1996-08-12 August 12, 96 2.5 2.5 1996-09-10 1996-10-01 1996-08-12
1995-09-11 September 11, 95 2.5 2.5 1995-09-11 1995-10-01 1995-08-22

Stock Rating Details for LYKALABS

Metric Value Recommendation
Overall Rating C Sell
DCF Score 5 Strong Buy
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 140.73 Cr 55.59 Cr 85.14 Cr 0.6050 0.00 Cr 36.41 Cr 50.50 Cr 8.01 Cr 2.25 20.17 Cr 0.0569
2024-03-31 105.13 Cr 45.19 Cr 59.94 Cr 0.5701 0.00 Cr 2.58 Cr 1.50 Cr -2.49 Cr -0.75 16.76 Cr -0.0237
2023-03-31 91.69 Cr 76.41 Cr 15.28 Cr 0.1667 0.00 Cr 2.88 Cr 1.61 Cr -13.21 Cr -4.57 12.85 Cr -0.1441
2022-03-31 183.59 Cr 53.30 Cr 130.28 Cr 0.7097 0.00 Cr 3.20 Cr 83.09 Cr 39.00 Cr 13.59 101.18 Cr 0.2124
2021-03-31 67.11 Cr 38.18 Cr 28.92 Cr 0.4310 0.00 Cr 2.25 Cr 11.36 Cr -11.55 Cr -4.07 20.12 Cr -0.1722

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 1.34 Cr 176.21 Cr 72.62 Cr 103.5502 Cr 39.18 Cr 37.84 Cr 12.47 Cr 77.10 Cr 0.00 Cr 0.00 Cr 0.02 Cr 46.6313 Cr
2024-03-31 5.95 Cr 156.72 Cr 88.46 Cr 68.1543 Cr 58.65 Cr 52.70 Cr 9.57 Cr 71.12 Cr 0.56 Cr 0.00 Cr 0.07 Cr 37.6402 Cr
2023-03-31 11.71 Cr 151.52 Cr 105.85 Cr 45.4406 Cr 75.10 Cr 62.92 Cr 6.95 Cr 63.76 Cr 0.00 Cr 0.00 Cr 0.04 Cr 32.5980 Cr
2022-03-31 17.05 Cr 185.61 Cr 172.12 Cr 13.3384 Cr 130.44 Cr 128.31 Cr 8.20 Cr 85.97 Cr 0.00 Cr 0.00 Cr 0.01 Cr 99.3527 Cr
2021-03-31 7.15 Cr 190.01 Cr 215.10 Cr -25.7967 Cr 162.63 Cr 162.40 Cr 4.31 Cr 84.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 49.8809 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 1.8994 Cr -11.7960 Cr 5.2920 Cr -13.7554 Cr -4.6047 Cr 1.3441 Cr -15.6548 Cr 8.0120 Cr -19.4695 Cr 0.0000 Cr -2.8937 Cr
2024-03-31 1.7733 Cr -9.4881 Cr 1.9528 Cr -7.4581 Cr -5.7620 Cr 5.9488 Cr -9.2314 Cr -2.4894 Cr -15.9830 Cr 0.0000 Cr -2.6175 Cr
2023-03-31 8.9526 Cr 7.3504 Cr -21.6427 Cr 0.7672 Cr -5.3397 Cr 11.7108 Cr -8.1854 Cr -13.1711 Cr -56.7815 Cr 0.0000 Cr 1.2439 Cr
2022-03-31 79.2461 Cr -6.1720 Cr -63.1773 Cr 71.7333 Cr 9.8969 Cr 17.0505 Cr -7.5129 Cr 59.2470 Cr -40.1915 Cr 0.0000 Cr -3.8919 Cr
2021-03-31 8.8115 Cr -0.1613 Cr -11.7982 Cr 7.5438 Cr -3.1480 Cr 7.1536 Cr -1.2678 Cr -14.1441 Cr -4.9130 Cr 0.0000 Cr 2.4266 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-12-31 30.73 Cr 23.20 Cr 7.53 Cr 0.2451 -0.51 Cr 0.00 Cr 0.00 2.81 Cr 0.0000
2025-09-30 36.66 Cr 27.43 Cr 9.23 Cr 0.2519 -4.69 Cr -3.36 Cr -0.94 -1.45 Cr -0.0916
2025-06-30 33.03 Cr 12.74 Cr 20.29 Cr 0.6143 1.57 Cr 0.93 Cr 0.25 4.32 Cr 0.0282
2025-03-31 34.25 Cr 13.08 Cr 21.16 Cr 0.6180 11.55 Cr 1.77 Cr 0.49 5.18 Cr 0.0517
2024-12-31 33.80 Cr 13.06 Cr 20.74 Cr 0.6136 3.36 Cr 2.71 Cr 0.75 6.02 Cr 0.0801

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-09-30 1.16 Cr 0.03 Cr 1.19 Cr 37.14 Cr 11.54 Cr 60.62 Cr 79.21 Cr 167.80 Cr 66.43 Cr
2025-06-30 0.00 Cr 0.00 Cr 1.84 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -103.58 Cr
2025-03-31 1.34 Cr 0.02 Cr 1.36 Cr 43.13 Cr 12.47 Cr 67.43 Cr 77.10 Cr 176.21 Cr 72.62 Cr
2024-12-31 0.00 Cr 0.00 Cr 1.13 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -98.69 Cr
2024-09-30 1.11 Cr 0.02 Cr 1.13 Cr 37.84 Cr 9.69 Cr 58.65 Cr 74.81 Cr 168.25 Cr 69.56 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-06-30 0.93 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2025-03-31 1.77 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 2.71 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 2.10 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 1.44 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Biotechnology

Company Name Symbol Price Market Cap Volume
Biocon Limited BIOCON ₹395.85 ₹502,400,431,478.00 ₹3,958,795.00
Anthem Biosciences Ltd. ANTHEM ₹704.10 ₹395,502,722,489.00 ₹355,793.00
Piramal Pharma Limited PPLPHARMA ₹161.06 ₹213,141,551,189.00 ₹1,291,793.00
Syngene International Limited SYNGENE ₹433.60 ₹174,199,573,542.00 ₹1,063,178.00
Onesource Specialty Pharma Ltd. ONESOURCE ₹1,292.80 ₹148,182,287,360.00 ₹112,142.00
Concord Biotech Limited CONCORDBIO ₹1,230.90 ₹128,772,085,504.00 ₹11,424,002.00
Jubilant Ingrevia Limited JUBLINGREA ₹593.30 ₹93,747,858,071.00 ₹117,147.00
Blue Jet Healthcare Limited BLUEJET ₹399.75 ₹69,342,803,644.00 ₹1,270,572.00
Supriya Lifescience Limited SUPRIYA ₹665.20 ₹53,537,158,560.00 ₹65,822.00
Zota Health Care Limited ZOTA ₹1,214.80 ₹36,848,109,294.00 ₹83,147.00
Dishman Carbogen Amcis Limited DCAL ₹175.53 ₹27,520,136,665.00 ₹195,704.00

Key Executives

MD, Chief Executive Officer, Promoter & Director
Kunal Narendra Gandhi

Gender: male

Year Born: 1987

Company Secretary & Compliance Officer
Shailendra Kumar Agrawal

Gender: male

Year Born: 1980

Chief Financial Officer & Executive Director
Yogesh Babulal Shah

Gender: male

Year Born: 1960

FAQs about Lyka Labs Limited

Who is the CEO of the company?

The CEO is Kunal Narendra Gandhi.

What is the current market price of the stock?

The current price is ₹61.82.

What is the 52-week price range?

The range is ₹60.2-128.78.

What is the market capitalization of the company?

The market capitalization is ₹220.64 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is -337.62.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Lyka Labs Limited (ISIN: INE933A01014) is a leading Biotechnology in India. With a market capitalization of ₹220.64 crores and an average daily volume of 27,212 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.